MedTrace Logo

Administration of Oral Probiotic Streptococcus Salivarius K12

NCT07757360 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-08-11

No results posted yet for this study

Summary

The clinical trial is investigating the oral administration of probiotic Streptococcus salivarius K12 in the form of lozenges in healthy adults.

The main outcome measures are:

* Potential for Streptococcus salivarius K12 to colonise the oral cavity
* Effect on other bacteria and Candida albicans in the oral cavity
* Possible anti-inflammatory effect

Participants will:

* Take one lozenge containing Streptococcus salivarius K12 daily for 4 weeks
* Attend 3 dental check-ups (before starting the probiotic treatment, and after 4 and 8 weeks)
* Collect their own saliva samples in accordance with a sampling schedule

Conditions

  • Oral Health

Interventions

DIETARY_SUPPLEMENT

Probiotic

The intervention consists of daily consumption of 1 lozenge BIOTICS-O for 4 weeks. BIOTICS-O are probiotic lozenges from the manufacturer Burgerstein Vitamine. They contain viable Streptococcus salivarius K12 (BLIS® K12, ATCC BAA-1024), 1 billion colony-forming units (CFU) per lozenge. BIOTICS-O is a dietary supplement available over the counter in Swiss pharmacies.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-06
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07757360 on ClinicalTrials.gov